Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet SyndromeGuruFocus · Oct 5, 2026
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16tGuruFocus · Sep 3, 2026This index is designed to gauge the price fluctuations of futures agreements tied to various commodities such as crude oil, heating oil, corn, wheat, gold, and aluminum. Furthermore, a T-Bill Index component aims to simulate the earnings generated by regularly investing in 3-month U.S. Treasury bills.